This Plain Language Summary from Immunotherapy describes the results of a study called POETYK PSO-2. The study looked at a new treatment called Deucravacitinib for a skin condition known as plaque psoriasis.

Read the full article here.

This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-2, which investigated a new treatment for plaque psoriasis. Plaque psoriasis appears on the body as dry, discolored, patches of skin that can be flaky and covered in scales. This can make the skin itch, crack or bleed and make it difficult for people with psoriasis to perform basic everyday tasks. Treatments are available, but some do not always reduce symptoms or may need to be injected or taken multiple times a day, which can be difficult to do, or can have undesirable side effects. Researchers are looking for new treatments for psoriasis

To see a video where the author gives an overview of the Plain Language Summary, see below.

The original article on which this Plain Language Summary of Publication is based is titled ‘Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial’ and was published in the Journal of the American Academy of Dermatology. Read the original article here.